Clinical Trial Update: HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of olaparib, palbociclib, and fulvestrant in BRCA mutation-associated, hormone receptor-positive breast cancer with met…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• IBRANCE (PALBOCICLIB)
• Lynparza (olaparib)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 1 | Status: COMPLETED